BioGX Inc. Gets Emergency FDA Approval for New COVID-19 Test

A Birmingham-based molecular diagnostics company announced on April 3 it has received FDA emergency authorization to produce and distribute a new diagnostic test that will enable hospitals to screen for COVID-19. BioGX Inc. made the announcement in conjunction with BD (Becton, Dickinson and Co. — NYSE: BDX), a leading global medical technology company. BioGX’s new…

Thank you for reading!

To continue reading this article you must be registered and logged into this site. If you already have an account please login now, otherwise you can click here to register for new account. Registration is FREE.

Login       Register